Patents by Inventor Johannes De Haard
Johannes De Haard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240033353Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.Type: ApplicationFiled: June 14, 2023Publication date: February 1, 2024Inventors: Johannes DE HAARD, Samson FUNG, Nicolas LEUPIN, Adrian OCHSENBEIN, Carsten RIETHER, Luc VAN ROMPAEY
-
Patent number: 11712468Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.Type: GrantFiled: December 18, 2019Date of Patent: August 1, 2023Assignees: ARGENX BV, University of BernInventors: Johannes De Haard, Samson Fung, Nicolas Leupin, Adrian Ochsenbein, Carsten Riether, Luc Van Rompaey
-
Patent number: 11505585Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: GrantFiled: November 22, 2017Date of Patent: November 22, 2022Assignees: argenx BV, The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Publication number: 20220275035Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: February 15, 2022Publication date: September 1, 2022Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Publication number: 20220177555Abstract: Methods for preparing engineered antibodies exhibiting improved pH-dependent antigen binding are disclosed. The methods are based on introduction of histidine residues at a subset of defined amino acid positions within the antibody CDRs. The set of amino acid positions selected for histidine substitution is derived from a heat-map of histidine occurrence within the CDRs of functional antibodies from a natural antibody repertoire. The methods provide a simpler and less time-consuming approach to the identification of pH-dependent antibody variants.Type: ApplicationFiled: May 10, 2018Publication date: June 9, 2022Inventors: Christophe BLANCHETOT, Erik HOFMAN, Johannes DE HAARD, Jacobus Cornelis RASSER
-
Publication number: 20220073604Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).Type: ApplicationFiled: August 10, 2021Publication date: March 10, 2022Inventors: Christophe BLANCHETOT, Johannes DE HAARD, Torsten DREIER, Natalie DE JONGE, Sebastian Paul VAN DER WONING, Nicolas ONGENAE
-
Patent number: 11117959Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).Type: GrantFiled: January 3, 2019Date of Patent: September 14, 2021Inventors: Christophe Blanchetot, Johannes De Haard, Torsten Dreier, Natalie De Jonge, Sebastian Paul Van Der Woning, Nicolas Ongenae
-
Publication number: 20200222532Abstract: The present invention provides combinations and methods using same for the treatment of malignancy, particularly a myeloid malignancy such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), chronic myeloid leukemia (CML), and chronic myelomonocytic leukemia (CMML). The combination may comprise an antibody or antigen-binding fragment thereof that binds to CD70, and an inhibitor of BCL-2. In certain embodiments, the antibody is ARGX-110 (cusatuzumab). In certain embodiments, the BCL-2 inhibitor is venetoclax. In certain embodiments, the combination provides synergistic treatment of AML. The combination may additionally comprise at least one additional anti-cancer agent.Type: ApplicationFiled: December 18, 2019Publication date: July 16, 2020Inventors: Johannes DE HAARD, Samson FUNG, Nicolas LEUPIN, Adrian OCHSENBEIN, Carsten RIETHER, Luc VAN ROMPAEY
-
Patent number: 10676535Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: December 26, 2017Date of Patent: June 9, 2020Assignee: argenx BVBAInventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Publication number: 20190233509Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).Type: ApplicationFiled: January 3, 2019Publication date: August 1, 2019Inventors: Christophe BLANCHETOT, Johannes DE HAARD, Torsten DREIER, Natalie DE JONGE, Sebastian Paul VAN DER WONING, Nicolas ONGENAE
-
Publication number: 20190194277Abstract: Provided are novel methods of treating generalized myasthenia gravis in a subject. These methods generally comprise administering to the subject an effective amount of an isolated FcRn antagonist. In certain embodiments the FcRn antagonist binds to FcRn with increased affinity and reduced pH dependence relative to native Fc region.Type: ApplicationFiled: December 7, 2018Publication date: June 27, 2019Inventors: Johannes de Haard, Torsten Dreier, Peter Ulrichts, Antonio Guglietta, Nicolas Leupin
-
Patent number: 10316073Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: GrantFiled: December 23, 2014Date of Patent: June 11, 2019Assignees: argenx BVBA, The Board of Regents of the University of Texas SystemInventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Patent number: 10183995Abstract: The present invention provides binding molecules (e.g., antibodies or antigen binding fragments thereof) that specifically bind to and inhibit the biological activity of IL-6 (e.g., human, mouse and non-human primate IL-6). In a preferred embodiment, the antibodies or antigen binding fragments of the invention bind to IL-6 and inhibit its binding to an IL-6 receptor. Such antibodies or antigen binding fragments are particularly useful for treating IL-6-associated diseases or disorders (e.g., inflammatory disease and cancer).Type: GrantFiled: May 23, 2013Date of Patent: January 22, 2019Assignee: ARGEN-X N.V.Inventors: Christophe Blanchetot, Johannes De Haard, Torsten Dreier, Natalie De Jonge, Sebastian Paul Van Der Woning, Nicolas Ongenae
-
Publication number: 20180215833Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: ApplicationFiled: December 26, 2017Publication date: August 2, 2018Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paolo MICHIELI, Cristina Basilico, Torsten DREIER
-
Publication number: 20180179258Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.Type: ApplicationFiled: November 22, 2017Publication date: June 28, 2018Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
-
Patent number: 9884917Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: December 6, 2013Date of Patent: February 6, 2018Assignee: ARGEN-X N.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Publication number: 20170349667Abstract: The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.Type: ApplicationFiled: May 16, 2017Publication date: December 7, 2017Inventors: Anna HULTBERG, Michael SAUNDERS, Johannes DE HAARD, Els FESTJENS, Natalie DE JONGE, Paulo MICHIELI
-
Patent number: 9688773Abstract: The invention provides a product combination or composition, and also multispecific antibodies comprising two or more antigen-binding sites (as antibodies or antigen binding fragments thereof), wherein two the antigen-binding bind to distinct non-overlapping epitopes of the human c-Met protein. The product combination or composition or multispecific antibody inhibits HGF-independent activation of the human c-Met receptor protein.Type: GrantFiled: November 3, 2011Date of Patent: June 27, 2017Assignee: ARGEN-X N.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge, Paolo Michieli, Cristina Basilico, Torsten Dreier
-
Patent number: 9688774Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: February 17, 2015Date of Patent: June 27, 2017Assignee: ARGEN-X N.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge
-
Patent number: 9631027Abstract: The present invention relates to antibodies that specifically bind to the human c-Met receptor protein and that act as strict antagonists of hepatocyte growth factor (HGF)-mediated activation of the c-Met receptor and also inhibit HGF-independent activation of the human c-Met protein.Type: GrantFiled: February 17, 2015Date of Patent: April 25, 2017Assignee: ARGEN-X N.V.Inventors: Anna Hultberg, Michael Saunders, Johannes De Haard, Els Festjens, Natalie De Jonge